Drawing for HIKMA.

USPTO serial 87725225

HIKMA.

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
LEE RISO, LOKSYE GEORGIANA
Law office
TMO LAW OFFICE 110 - SENIOR ATTORNEY

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 600: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with HIKMA.?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark S. Leonardo

Mark S. Leonardo Brown Rudnick LLPOne Financial CenterBoston, MA 02111UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical, medicinal, and veterinary preparations and substances, namely, systemic anti-infectives, pharmaceutical and medicinal substances for the prevention, curing, and treatment of viral, metabolic, alimentary, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, parasitic, psychiatric, and immune system related diseases and disorders, pharmaceutical and medicinal substances for the prevention, curing, and treatment of allergies, inflammation, pain, infectious diseases, blood diseases and disorders, nervous system diseases and disorders, malignant neoplastic diseases and disorders, and immunomodulating agent diseases and disorders; chemical preparations for pharmaceutical or medical purposes, namely, for viral, metabolic, alimentary, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, parasitic, psychiatric, and immune system related diseases and disorders, allergies, inflammation, pain, infectious diseases, blood diseases and disorders, nervous system diseases and disorders, malignant neoplastic diseases and disorders, and immunomodulating agent diseases and disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 5, 2019MAB0ABANDONMENT NOTICE MAILED - INCOMPLETE RESPONSE—
Dec 5, 2019ABN0ABANDONMENT - INCOMPLETE RESPONSE—
Dec 4, 2019DPCCDIVISIONAL PROCESSING COMPLETE—
Dec 3, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 2, 2019CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 2, 2019PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Nov 27, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 21, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 21, 2019ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Nov 18, 2019DRRRDIVISIONAL REQUEST RECEIVED—
Nov 18, 2019ERTDTEAS REQUEST TO DIVIDE RECEIVED—
May 29, 2019GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
May 29, 2019GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 29, 2019CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 13, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 13, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 13, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 13, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 13, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 14, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 14, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 14, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Nov 9, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 9, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 9, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 13, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 13, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 13, 2018ALIEASSIGNED TO LIE—
Sep 26, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 28, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 28, 2018DOCKASSIGNED TO EXAMINER—
Jan 4, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 21, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance